Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. [electronic resource]
Producer: 20010531Description: 57-63 p. digitalISSN:- 0959-4973
- Animals
- Antineoplastic Agents, Phytogenic -- administration & dosage
- Cell Cycle -- drug effects
- Female
- Humans
- Lymphoma, Non-Hodgkin -- drug therapy
- Maximum Tolerated Dose
- Mice
- Mice, Inbred ICR
- Mice, SCID
- Neovascularization, Pathologic -- drug therapy
- Prodrugs -- administration & dosage
- Stilbenes -- administration & dosage
- Survival Rate
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.